Delic Labs President and CSO Dr. Markus Roggen to Discuss the Importance of R&D for Business Growth at MJBizCon
Delic Holdings Corp, a leader in innovative cannabis and psychedelic treatments, announced that Dr. Markus Roggen, its President and Chief Science Officer, will be speaking at the MJBizCon on November 15, 2022 in Las Vegas. He will participate in a panel discussion titled R&D As a Business Tool: Maximizing Revenue by Focusing on The Scientific Method, emphasizing the significance of research and development in driving revenue. This event expects over 35,000 attendees and 1,400 exhibitors, showcasing networking opportunities and industry insights.
- Participation of Dr. Markus Roggen in a prominent industry event enhances company visibility.
- Focus on research and development as a revenue maximization strategy may strengthen brand differentiation.
- None.
Dr. Markus Roggen, President and Chief Science Officer for Delic Labs, will participate in a panel discussion about building scientific trust and using research and development to differentiate a brand and maximize revenues
VANCOUVER, BC, Oct. 27, 2022 /PRNewswire/ - Delic Holdings Corp ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today shared details regarding Delic Labs President and CSO Dr. Markus Roggen's participation at the 11th annual MJBizCon in Las Vegas, Nevada on November 15, 2022.
- MJBizScience Symposium
November 15, 2022
With over 1,400 exhibitors, 35,000 attendees and countless networking opportunities, MJBizCon is the world's premier cannabis business conference and tradeshow. At this year's conference, Dr. Markus Roggen will participate in MJBizScience Symposium's panel discussion entitled, R&D As a Business Tool: Maximizing Revenue by Focusing on The Scientific Method. Alongside leading professionals within the cannabis industry, Roggen will highlight the foundational importance of research and development and explain how good science can help a company's bottom line. For those in attendance at this year's MJBizCon, the panel discussion is scheduled to begin at 11:20 a.m. on November 15, 2022, at the Westgate Resort in Las Vegas, Nevada. To register for this year's conference, please visit https://mjbizconference.com/.
Delic Labs is a federally licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development. Based at the University of British Columbia in Vancouver, Canada and founded by award-winning chemists Dr. Markus Roggen and UBC Professor Dr. Glenn Sammis, Delic Labs uses precision chemical analytics and metabolomics identification to develop IP, produce novel products for patients, and advance the cannabis and psychedelic wellness industries. Part of the Delic Corp family, the leading psychedelic wellness platform, Delic Labs powers innovation and treatment options with an ever-expanding line of unique and high-quality products for markets that allow legal cannabis and psychedelic-based care.
Forward-Looking Information and Statements
This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein may include, but are not limited to: information regarding the timing or terms upon which the Transaction will be completed; potential benefits of the Transaction; anticipated continued growth in the health and wellness sector (and, in particular, related to psychedelics); the ability of Delic to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.
By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Transaction not closing as planned or at all or on terms and conditions set forth in the Merger Agreement; incorrect assessment of the value and potential benefits of the Transaction; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.
In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions. These assumptions include, but are not limited to: assumptions as to the time required to negotiate a definite agreement and complete matters related to the Transaction; the ability to consummate the Transaction; the ability of the parties to obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of other conditions to the consummation of the Transaction on the proposed terms; the potential impact of the announcement or consummation of the Transaction on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time on the Transaction.
Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.
Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.
View original content to download multimedia:https://www.prnewswire.com/news-releases/delic-labs-president-and-cso-dr-markus-roggen-to-discuss-the-importance-of-rd-for-business-growth-at-mjbizcon-301661140.html
SOURCE Delic Holdings Inc.
FAQ
What is Delic's participation in MJBizCon on November 15, 2022?
Where will the MJBizCon take place?
What is the importance of R&D according to Delic's Dr. Markus Roggen?
How many attendees are expected at MJBizCon 2022?
What can attendees expect from MJBizCon 2022?
